OcellO brings high content imaging and advanced tumor organoid analytic technology that will enrich our preclinical 3D in vitro oncology and immuno-oncology service platforms.

BiTEs are a robust class of immuno-oncology (I/O) therapy which are engineered proteins that redirect T cells to destroy targeted tumor cells. Join Dr. Ludovic Bourre to discuss the translational challenges in BiTE development and to explore how next-generation preclinical models can be used to provide critical insights in early-stage BiTE development.

Presented by Dr Yujun Huang this webinar will discuss how co-culturing tumor organoids with immune cells offers a unique opportunity to interrogate novel immunotherapies.

Join our complimentary virtual oncology event running in parallel to AACR 2021, where we are hosting a virtual booth, which will include the opportunity to view our 14 posters accepted by AACR in our virtual poster hall. Additionally, visit our booth to meet with our scientists and access a variety of resources.

This White Paper details how patient-derived tumor organoids are revolutionizing drug discovery by providing more translational and predictive data in matrixed, high-throughput screening (HTS) approaches.

Presented by Dr Rajendra Kumari this webinar will discuss new advances in 3D tumor modelling and how these are contributing to reshaping model choice in drug development. She will review benefits and limitations from available 2D and 3D in vitro tumor models, introduce organoids, and discuss the need for multiple tools and in depth expertise to unravel early stage data and progress successful candidates.

Explore our new NGS-based murine targeted panel for I/O and TME studies. Learn how to leverage the panel to gain in-depth genomic insight into immune cell populations and the I/O pathways and processes of your murine immunity pharmacology study samples.

Learn how to leverage the novel HuGEMM™ human target knock-in models to study toxicities associated with human-specific immunotherapies. Explore how both the efficacy and toxicity of your immuno-oncology compound can be assessed in the same animal model system to accelerate your drug discovery programs.

Learn how to select the right in vitro platform for each stage of your drug development program based on model features, benefits, and limitations. Explore the optimal applications of tumor organoids, a superior and predictive research system for oncology drug development, and how to best utilize them alongside conventional platforms.

Join Dr Yinfei Yin to explore the benefits of optical imaging in preclinical oncology research with an emphasis on immunotherapy development. Learn how imaging improves the predictive power of preclinical studies, and allows a more efficient and cost-effective translation into the clinic. Key new imaging models for evaluating novel anticancer agents will also be discussed.

Join Dr Davy Ouyang to discover the latest cutting edge syngeneic research driving immuno-oncology development. Learn more about deep kinetic profiling, and how immune cell depletion studies are used to explore mediation of immunotherapy response. Engineered and bioluminescent syngeneics will also be discussed, as well as novel I/O platforms for moving beyond standard syngeneic studies.

Explore whole-transcriptomic analysis of tumor and matched normal tissues from Chinese ccRCC patients, to investigate differences in expression profiles across Chinese and Caucasian populations. Discover how genomic analysis of clinical samples has the potential to guide patient stratification.

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.